Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

30 Jun 2011 13:18

RNS Number : 4784J
Omega Diagnostics Group PLC
30 June 2011
 



30 June 2011 AIM: ODX

 

Omega Diagnostics Group PLC

("Omega" or "the Company")

 

Directorate Change

 

Omega, the AIM listed medical diagnostics company, announces that Jag Grewal will join the Board as an Executive Director with immediate effect.

 

Jag Grewal, aged 42, joined the Company on 6 June 2011 as Group Sales and Marketing Director. Jag has worked in diagnostics for over 20 years having started out as a Clinical Biochemist in the NHS. In 1995, he joined Beckman Instruments where he developed a career spanning 15 years in sales and marketing holding a variety of positions in sales, product management and marketing management.

 

In 2009, Jag left as Northern Europe Marketing Manager to join Serco Health where he helped create the first joint venture within UK pathology between Serco Health and Guys and St Thomas' Hospital NHS Foundation Trust. Jag is also past Chairman and current treasurer of the British In-Vitro Diagnostics Association (BIVDA).

 

Andrew Shepherd, the Company's Chief Executive said: "We are very pleased to welcome Jag to the Board and his wealth of experience will be beneficial as we expand the scale of the Group's sales and marketing function in line with our expansion plans."

 

 

For further enquiries please contact:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel: 020 7397 8900

Ian Soanes

Elizabeth Bowman

Walbrook PR Limited

Paul McManus

Tel: 020 7933 8787

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

Fiona Henson

Tel: 020 7933 8795

Mob: 07886 335 992

fiona.henson@walbrookpr.com

 

 

 

Additional information:

 

Jag Grewal, aged 42, holds no shares in the Company and other than as set out below, there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Mr Grewal's appointment today as a Director of the Company.

 

Mr Grewal is a director / partner or has been a director / partner of the following companies / partnerships during the previous five years:

 

British In-Vitro Diagnostics Association

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAWGUQGQUPGGPU
Date   Source Headline
16th Sep 202211:13 amRNSPurchase of Shares by Directors
13th Sep 20227:00 amRNSInvestor presentation and Confirmation of AGM
12th Sep 20227:00 amRNSFinal Results
2nd Sep 202210:15 amRNSHolding(s) in Company
31st Aug 20227:00 amRNSChange of preliminary results date
12th Aug 20227:00 amRNSChange of preliminary results date
8th Aug 20227:00 amRNSConfirmation of Preliminary Results
5th Aug 202212:09 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSCompletion of Sale of the CD4 Business
11th Jul 20227:00 amRNSPayment received
4th Jul 20227:00 amRNSHeads of Terms agreed for Sale of CD4 Business
23rd Jun 20223:13 pmRNSHolding(s) in Company
10th Jun 20227:00 amRNSGrant of share incentive awards
8th Jun 20221:47 pmRNSPDMR/Director Dealing
6th Jun 20222:29 pmRNSResult of General Meeting and Total Voting Rights
1st Jun 20227:00 amRNSResult of Open Offer
13th May 202210:05 amRNSPosting of Circular and Notice of General Meeting
11th May 20223:28 pmRNSHolding(s) in Company
6th May 20227:01 amRNSInvestor presentation
6th May 20227:00 amRNSPlacing, Subscription and Open Offer
7th Apr 20227:00 amRNSTrading Update
11th Mar 20227:00 amRNSUpdate on validation under CTDA legislation
8th Mar 20224:41 pmRNSSecond Price Monitoring Extn
8th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20224:41 pmRNSSecond Price Monitoring Extn
7th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20223:40 pmRNSResult of General Meeting
7th Mar 202211:03 amRNSConfirmation of Sale of Alva business
1st Mar 20227:00 amRNSResult of Open Offer
18th Feb 20227:00 amRNSInvestor Meeting
14th Feb 20222:06 pmRNSSecond Price Monitoring Extn
14th Feb 20222:01 pmRNSPrice Monitoring Extension
11th Feb 202211:05 amRNSSecond Price Monitoring Extn
11th Feb 202211:00 amRNSPrice Monitoring Extension
11th Feb 20227:01 amRNSFundraising to raise gross proceeds of up to £7m
11th Feb 20227:00 amRNSSale of Alva manufacturing business
10th Feb 20222:06 pmRNSSecond Price Monitoring Extn
10th Feb 20222:00 pmRNSPrice Monitoring Extension
10th Feb 20221:33 pmRNSSpeculation regarding a potential fundraise
8th Feb 20224:41 pmRNSSecond Price Monitoring Extn
8th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSCE-Mark for self-test for VISITECT® COVID-19 test
2nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20224:36 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSSpeculation regarding a potential fundraise
19th Jan 20227:00 amRNSDirectorate Change
10th Jan 20223:20 pmRNSConfirmation of detection of Omicron variant
4th Jan 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.